Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (nk-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: laropiprant, vidupiprant, asapiprant | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10638
Sealed predictions
- PTGDR in dopamine neurons, braak+0.24 (p 0.536) → +0.12 (p 0.768)receipt 10645
Swarm cases
receipt 10645: PTGDR in dopamine neurons, braak
- power
- full sample +0.41 (p 0.095, n 18), 95% CI -0.08 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.142, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.36 (p 0.142, n 18). could be the mix.
- skeptic
- leave-one-out range +0.33 to +0.48, sign flips 0; without severely affected donors +0.41 (p 0.095, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PTGDR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts